Andres McAllister

BioInvent's CMO comments on the ESMO presentation

BioInvent's CMO comments on the presentation at ESMO

BioInvent and Transgene presented promising Phase I/IIa data for BT-001 at ESMO in Barcelona over the weekend. BioStock contacted BioInvent's CMO...

Intervju
BioInvent to present promising clinical data at ASCO and EHA

BioInvent presents promising clinical data at ASCO and EHA

In the coming weeks, BioInvent will present...
BioInvent comments on the progress in the breast cancer study

BioInvent comments on progress in breast cancer study

BioInvent's pipeline consists of five drug candidates that are advancing...

Intervju
DexTech advances towards clinical studies

BioInvent's CMO comments on phase I/IIa data with BI-1808

BioInvent's phase I/IIa study with the first-in-class anti-TNFR2 antibody BI-1808 in...

Intervju
BioInvent's CFO on the company's business strategy

BioInvent's CFO on the company's business strategy

With a reported cash flow of just over 1,5 billion...

Intervju
BioInvent LLS TAP

CMO provides insight into new BioInvent collaboration

From achieving a strong ownership base, a...

Intervju

BioInvent's CMO on new positive data with BI-1206

BioInvent has presented more positive interim data from the company's...

Intervju